Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Changes in chemsex and sexual behaviour over time, among a cohort of MSM in London and Brighton: Findings from the AURAH2 study.

Sewell J, Cambiano V, Speakman A, Lampe FC, Phillips A, Stuart D, Gilson R, Asboe D, Nwokolo N, Clarke A, Rodger AJ.

Int J Drug Policy. 2019 Jun;68:54-61. doi: 10.1016/j.drugpo.2019.03.021. Epub 2019 Apr 15.

2.

Determining the Origins of Human Immunodeficiency Virus Type 1 Drug-resistant Minority Variants in People Who Are Recently Infected Using Phylogenetic Reconstruction.

Mbisa JL, Kirwan P, Tostevin A, Ledesma J, Bibby DF, Brown A, Myers R, Hassan AS, Murphy G, Asboe D, Pozniak A, Kirk S, Gill ON, Sabin C, Delpech V, Dunn DT; UK HIV Drug Resistance Database .

Clin Infect Dis. 2019 Sep 13;69(7):1136-1143. doi: 10.1093/cid/ciy1048.

PMID:
30534981
3.

The people living with HIV stigma survey UK 2015: HIV-related sexual rejection and other experiences of stigma and discrimination among gay and heterosexual men.

Hibbert M, Crenna-Jennings W, Kirwan P, Benton L, Lut I, Okala S, Asboe D, Jeffries J, Kunda C, Mbewe R, Morris S, Morton J, Nelson M, Thorley L, Paterson H, Ross M, Reeves I, Sharp L, Sseruma W, Valiotis G, Wolton A, Jamal Z, Hudson A, Delpech V.

AIDS Care. 2018 Sep;30(9):1189-1196. doi: 10.1080/09540121.2018.1479027. Epub 2018 May 27.

PMID:
29806466
4.

Cohort profile: The Pharmacokinetic and clinical Observations in PeoPle over fiftY (POPPY) study.

Bagkeris E, Burgess L, Mallon PW, Post FA, Boffito M, Sachikonye M, Anderson J, Asboe D, Garvey L, Vera J, Williams I, Johnson M, Babalis D, De Francesco D, Winston A, Sabin CA.

Int J Epidemiol. 2018 Oct 1;47(5):1391-1392e. doi: 10.1093/ije/dyy072. No abstract available.

5.

Changes in recreational drug use, drug use associated with chemsex, and HIV-related behaviours, among HIV-negative men who have sex with men in London and Brighton, 2013-2016.

Sewell J, Cambiano V, Miltz A, Speakman A, Lampe FC, Phillips A, Stuart D, Gilson R, Asboe D, Nwokolo N, Clarke A, Hart G, Rodger A.

Sex Transm Infect. 2018 Nov;94(7):494-501. doi: 10.1136/sextrans-2017-053439. Epub 2018 Apr 26.

6.

Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data.

Stirrup OT, Dunn DT, Tostevin A, Sabin CA, Pozniak A, Asboe D, Cox A, Orkin C, Martin F, Cane P; UK HIV Drug Resistance Database; UK Collaborative HIV Cohort.

AIDS Res Ther. 2018 Apr 16;15(1):11. doi: 10.1186/s12981-018-0198-7.

7.

2016 United Kingdom national guideline on the sexual health care of men who have sex with men.

Clutterbuck D, Asboe D, Barber T, Emerson C, Field N, Gibson S, Hughes G, Jones R, Murchie M, Nori AV, Rayment M, Sullivan A.

Int J STD AIDS. 2018 Jan 1:956462417746897. doi: 10.1177/0956462417746897. [Epub ahead of print]

PMID:
29334885
8.

Eligibility for PrEP among MSM attending GUM clinics in the UK.

Miltz AR, Cambiano V, Lampe FC, Sewell J, Speakman A, Phillips AN, Ivens DR, Asboe D, Collins S, Brady M, Nwokolo NC, Rodger AJ; AURAH Study Group.

Sex Transm Infect. 2017 Dec;93(8):571. doi: 10.1136/sextrans-2017-053268. No abstract available.

PMID:
29175993
9.

Clinically significant depressive symptoms and sexual behaviour among men who have sex with men.

Miltz AR, Rodger AJ, Sewell J, Speakman A, Phillips AN, Sherr L, Gilson RJ, Asboe D, Nwokolo NC, Clarke A, Gompels MM, Allan S, Collins S, Lampe FC; AURAH Study Group.

BJPsych Open. 2017 May 8;3(3):127-137. doi: 10.1192/bjpo.bp.116.003574. eCollection 2017 May.

10.

Poly drug use, chemsex drug use, and associations with sexual risk behaviour in HIV-negative men who have sex with men attending sexual health clinics.

Sewell J, Miltz A, Lampe FC, Cambiano V, Speakman A, Phillips AN, Stuart D, Gilson R, Asboe D, Nwokolo N, Clarke A, Collins S, Hart G, Elford J, Rodger AJ; Attitudes to and Understanding of Risk of Acquisition of HIV (AURAH) Study Group.

Int J Drug Policy. 2017 May;43:33-43. doi: 10.1016/j.drugpo.2017.01.001. Epub 2017 Feb 10.

PMID:
28189979
11.

Development, Validation, and Field-Testing of an Instrument for Clinical Assessment of HIV-Associated Neuropathy and Neuropathic Pain in Resource-Restricted and Large Population Study Settings.

Woldeamanuel YW, Kamerman PR, Veliotes DG, Phillips TJ, Asboe D, Boffito M, Rice AS.

PLoS One. 2016 Oct 20;11(10):e0164994. doi: 10.1371/journal.pone.0164994. eCollection 2016.

12.

Low levels of neurocognitive impairment detected in screening HIV-infected men who have sex with men: The MSM Neurocog Study.

Barber TJ, Bansi L, Pozniak A, Asboe D, Nelson M, Moyle G, Davies N, Margetts A, Ratcliffe D, Catalan J, Boffito M, Gazzard B.

Int J STD AIDS. 2017 Jun;28(7):715-722. doi: 10.1177/0956462416665061. Epub 2016 Aug 10.

PMID:
27510645
13.

Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom.

Tostevin A, White E, Dunn D, Croxford S, Delpech V, Williams I, Asboe D, Pozniak A, Churchill D, Geretti AM, Pillay D, Sabin C, Leigh-Brown A, Smit E; UK HIV Drug Resistance Database.

HIV Med. 2017 Mar;18(3):204-213. doi: 10.1111/hiv.12414. Epub 2016 Aug 1.

14.

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy.

Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, van Lunzen J, Corbelli GM, Estrada V, Geretti AM, Beloukas A, Asboe D, Viciana P, Gutiérrez F, Clotet B, Pradier C, Gerstoft J, Weber R, Westling K, Wandeler G, Prins JM, Rieger A, Stoeckle M, Kümmerle T, Bini T, Ammassari A, Gilson R, Krznaric I, Ristola M, Zangerle R, Handberg P, Antela A, Allan S, Phillips AN, Lundgren J; PARTNER Study Group.

JAMA. 2016 Jul 12;316(2):171-81. doi: 10.1001/jama.2016.5148. Erratum in: JAMA. 2016 Aug 9;316(6):667. JAMA. 2016 Nov 15;316(19):2048.

PMID:
27404185
15.

Attitudes to and Understanding of Risk of Acquisition of HIV Over Time: Design and Methods for an Internet-based Prospective Cohort Study Among UK Men Who Have Sex With Men (the AURAH2 Study).

Sewell J, Speakman A, Phillips AN, Cambiano V, Lampe FC, Gilson R, Asboe D, Nwokolo N, Clarke A, Ogilvy A, Collins S, Rodger AJ.

JMIR Res Protoc. 2016 Jun 15;5(2):e128. doi: 10.2196/resprot.5582.

16.

Comparison of efavirenz and protease inhibitor based combination antiretroviral therapy regimens in treatment-naïve people living with HIV with baseline resistance.

Lim C, McFaul K, Kabagambe S, Sonecha S, Jones R, Asboe D, Pozniak A, Nwokolo N, Boffito M.

AIDS. 2016 Jul 17;30(11):1849-52. doi: 10.1097/QAD.0000000000001140.

PMID:
27139315
17.

A cross-sectional study to evaluate the association of hyperbilirubinaemia on markers of cardiovascular disease, neurocognitive function, bone mineral density and renal markers in HIV-1 infected subjects on protease inhibitors.

Barber TJ, Moyle G, Hill A, Jagjit Singh G, Scourfield A, Yapa HM, Waters L, Asboe D, Boffito M, Nelson M.

HIV Clin Trials. 2016 May;17(3):123-30. doi: 10.1080/15284336.2016.1176305.

PMID:
27125367
18.

A Cross-Sectional Study on Attitudes to and Understanding of Risk of Acquisition of HIV: Design, Methods and Participant Characteristics.

Sewell J, Speakman A, Phillips AN, Lampe FC, Miltz A, Gilson R, Asboe D, Nwokolo N, Scott C, Day S, Fisher M, Clarke A, Anderson J, O'Connell R, Apea V, Dhairyawan R, Gompels M, Farazmand P, Allan S, Mann S, Dhar J, Tang A, Sadiq ST, Taylor S, Collins S, Sherr L, Hart G, Johnson AM, Miners A, Elford J, Rodger A.

JMIR Res Protoc. 2016 Apr 18;5(2):e58. doi: 10.2196/resprot.4873.

19.

HLA Immunogenotype Determines Persistent Human Papillomavirus Virus Infection in HIV-Infected Patients Receiving Antiretroviral Treatment.

Meys R, Purdie KJ, de Koning MN, Quint KD, Little AM, Baker F, Francis N, Asboe D, Hawkins D, Marsh SG, Harwood CA, Gotch FM, Bunker CB.

J Infect Dis. 2016 Jun 1;213(11):1717-24. doi: 10.1093/infdis/jiw038. Epub 2016 Feb 9.

PMID:
26908737
20.

A phylotype-based analysis highlights the role of drug-naive HIV-positive individuals in the transmission of antiretroviral resistance in the UK.

Mourad R, Chevennet F, Dunn DT, Fearnhill E, Delpech V, Asboe D, Gascuel O, Hue S; UK HIV Drug Resistance Database & the Collaborative HIV, Anti-HIV Drug Resistance Network.

AIDS. 2015 Sep 24;29(15):1917-25. doi: 10.1097/QAD.0000000000000768.

PMID:
26355570
21.

Evidence of Self-Sustaining Drug Resistant HIV-1 Lineages Among Untreated Patients in the United Kingdom.

Mbisa JL, Fearnhill E, Dunn DT, Pillay D, Asboe D, Cane PA; UK HIV Drug Resistance Database.

Clin Infect Dis. 2015 Sep 1;61(5):829-36. doi: 10.1093/cid/civ393. Epub 2015 May 19.

PMID:
25991470
22.

Transmitted antiretroviral resistance in a large HIV directorate 2011-2014: a response.

McFaul KM, Lim C, Jones R, Asboe D, Pozniak A, Sonecha S, Nwokolo N, Boffito M.

AIDS. 2015 Apr 24;29(7):861-2. doi: 10.1097/QAD.0000000000000601. No abstract available.

PMID:
25985410
23.

Transmitted antiretroviral drug resistance in treatment naïve HIV-infected persons in London in 2011 to 2013.

McFaul K, Lim C, Jones R, Asboe D, Pozniak A, Sonecha S, Boffito M, Nwokolo N.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19747. doi: 10.7448/IAS.17.4.19747. eCollection 2014.

24.

HIV testing and management of newly diagnosed HIV.

Rayment M, Asboe D, Sullivan AK.

BMJ. 2014 Jul 8;349:g4275. doi: 10.1136/bmj.g4275. Review. No abstract available.

PMID:
25005147
25.

Pharmacology lessons from chemoprophylaxis studies.

Boffito M, Jackson A, Asboe D.

Clin Infect Dis. 2014 Jul;59 Suppl 1:S52-4. doi: 10.1093/cid/ciu250.

PMID:
24926035
26.

HIV-related neurocognitive impairment screening: the patient's perspective on its utility and psychological impact.

Nightingale A, Ratcliffe D, Leonidou L, Margetts A, Asboe D, Gazzard B, Catalan J, Barber TJ.

AIDS Care. 2014;26(8):1036-41. doi: 10.1080/09540121.2014.894619. Epub 2014 Mar 13.

PMID:
24625218
27.

Persistence of HIV-1 transmitted drug resistance mutations.

Castro H, Pillay D, Cane P, Asboe D, Cambiano V, Phillips A, Dunn DT; UK Collaborative Group on HIV Drug Resistance.

J Infect Dis. 2013 Nov 1;208(9):1459-63. doi: 10.1093/infdis/jit345. Epub 2013 Jul 31.

28.

Screening for HIV-related neurocognitive impairment in clinical practice: challenges and opportunities.

Barber TJ, Bradshaw D, Hughes D, Leonidou L, Margetts A, Ratcliffe D, Thornton S, Pozniak A, Asboe D, Mandalia S, Boffito M, Davies N, Gazzard B, Catalan J.

AIDS Care. 2014 Feb;26(2):160-8. doi: 10.1080/09540121.2013.819401. Epub 2013 Jul 22. Review.

PMID:
23869661
29.

HPV vaccination to prevent anal cancer in men who have sex with men.

Lawton MD, Nathan M, Asboe D.

Sex Transm Infect. 2013 Aug;89(5):342-3. doi: 10.1136/sextrans-2013-051176. No abstract available.

PMID:
23858494
30.

Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone.

Waters L, Bansi L, Asboe D, Pozniak A, Smit E, Orkin C, Fearnhill E, Dunn D, Phillips A; UK CHIC Study; UK HIV Drug Resustance Database.

Antivir Ther. 2013;18(2):213-9.

PMID:
23653911
31.

Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe.

De Luca A, Dunn D, Zazzi M, Camacho R, Torti C, Fanti I, Kaiser R, Sönnerborg A, Codoñer FM, Van Laethem K, Vandamme AM, Bansi L, Ghisetti V, van de Vijver DA, Asboe D, Prosperi MC, Di Giambenedetto S; SEHERE collaboration in Chain.

J Infect Dis. 2013 Apr 15;207(8):1216-20. doi: 10.1093/infdis/jit017. Epub 2013 Jan 11.

PMID:
23315324
32.

A dedicated clinic for HIV-positive individuals over 50 years of age: a multidisciplinary experience.

Waters L, Patterson B, Scourfield A, Hughes A, de Silva S, Gazzard B, Barton S, Asboe D, Pozniak A, Boffito M.

Int J STD AIDS. 2012 Aug;23(8):546-52. doi: 10.1258/ijsa.2012.011412.

PMID:
22930290
33.

Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study.

UK Collaborative Group on HIV Drug Resistance, Dolling D, Sabin C, Delpech V, Smit E, Pozniak A, Asboe D, Brown AL, Churchill D, Williams I, Geretti AM, Phillips A, Mackie N, Murphy G, Castro H, Pillay D, Cane P, Dunn D, Dolling D.

BMJ. 2012 Aug 21;345:e5253. doi: 10.1136/bmj.e5253.

34.

Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor.

Barber TJ, Harrison L, Asboe D, Williams I, Kirk S, Gilson R, Bansi L, Pillay D, Dunn D; UK HIV Drug Resistance Database and UK Collaborative HIV Cohort (UK CHIC) Study Steering Committees.

J Antimicrob Chemother. 2012 Apr;67(4):995-1000. doi: 10.1093/jac/dkr569. Epub 2012 Jan 17.

PMID:
22258921
35.

British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011.

Asboe D, Aitken C, Boffito M, Booth C, Cane P, Fakoya A, Geretti AM, Kelleher P, Mackie N, Muir D, Murphy G, Orkin C, Post F, Rooney G, Sabin C, Sherr L, Smit E, Tong W, Ustianowski A, Valappil M, Walsh J, Williams M, Yirrell D; BHIVA Guidelines Subcommittee.

HIV Med. 2012 Jan;13(1):1-44. doi: 10.1111/j.1468-1293.2011.00971.x. No abstract available.

36.

Reduced T(H)1/T(H)17 CD4 T-cell numbers are associated with impaired purified protein derivative-specific cytokine responses in patients with HIV-1 infection.

Clark S, Page E, Ford T, Metcalf R, Pozniak A, Nelson M, Henderson DC, Asboe D, Gotch F, Gazzard BG, Kelleher P.

J Allergy Clin Immunol. 2011 Oct;128(4):838-846.e5. doi: 10.1016/j.jaci.2011.05.025. Epub 2011 Jul 13.

PMID:
21745684
37.

Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data.

Price H, Asboe D, Pozniak A, Gazzard B, Fearnhill E, Pillay D, Dunn D; UK Collaborative Group on HIV Drug Resistance; UK Collaborative HIV Cohort Study.

Antivir Ther. 2010;15(2):203-11. doi: 10.3851/IMP1511.

PMID:
20386075
38.

Re-emergent hepatitis C viremia after apparent clearance in HIV-positive men who have sex with men: reinfection or late recurrence?

Jones R, Brown D, Nelson M, Low E, Bhagani S, Atkins M, Danta M, Dusheiko G, Pybus O, Asboe D.

J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):547-50. doi: 10.1097/QAI.0b013e3181ba41e2. No abstract available. Erratum in: J Acquir Immune Defic Syndr. 2010 May 1;54(1):112.

PMID:
20220378
39.

Unselected hepatitis C screening of men who have sex with men attending sexual health clinics.

Scott C, Day S, Low E, Sullivan A, Atkins M, Asboe D.

J Infect. 2010 May;60(5):351-3. doi: 10.1016/j.jinf.2010.01.013. Epub 2010 Feb 12.

PMID:
20153770
40.

The impact of the 0-0 cell on measures of amino acid covariation.

Dunn D, von Wyl V, Price H, Asboe D.

AIDS. 2010 Jan 2;24(1):159-60. doi: 10.1097/QAD.0b013e32833156ab. No abstract available.

PMID:
19952543
41.

The International Index of Erectile Function: development of an adapted tool for use in HIV-positive men who have sex with men.

Coyne K, Mandalia S, McCullough S, Catalan J, Noestlinger C, Colebunders R, Asboe D.

J Sex Med. 2010 Feb;7(2 Pt 1):769-74. doi: 10.1111/j.1743-6109.2009.01579.x. Epub 2009 Nov 12.

PMID:
19912494
42.

Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers.

Boffito M, Jackson A, Lamorde M, Back D, Watson V, Taylor J, Waters L, Asboe D, Gazzard B, Pozniak A.

J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):222-7. doi: 10.1097/QAI.0b013e3181b061d0.

PMID:
19620877
43.

Successful use of darunavir, etravirine, enfuvirtide and tenofovir/emtricitabine in pregnant woman with multiclass HIV resistance.

Furco A, Gosrani B, Nicholas S, Williams A, Braithwaite W, Pozniak A, Taylor G, Asboe D, Lyall H, Shaw A, Kapembwa M.

AIDS. 2009 Jan 28;23(3):434-5. doi: 10.1097/QAD.0b013e32832027d6. No abstract available.

PMID:
19188762
44.

Acne vulgaris and acne rosacea as part of immune reconstitution disease in HIV-1 infected patients starting antiretroviral therapy.

Scott C, Staughton RC, Bunker CJ, Asboe D.

Int J STD AIDS. 2008 Jul;19(7):493-5. doi: 10.1258/ijsa.2008.008026.

PMID:
18574128
45.

Simvastatin co-prescribed with protease inhibitors despite dangerous drug interactions.

Coyne KM, Boffito M, Theobald N, Asboe D.

Sex Transm Infect. 2007 Oct;83(6):498. No abstract available.

46.

The extent of self-initiated STI and HIV prophylaxis (auto-PEP) and treatment in MSM attending GUM and HIV clinic services.

Menon-Johansson AS, Randell P, Mandalia S, Asboe D, Boag FC.

Sex Transm Infect. 2007 Oct;83(6):498-9. No abstract available. Erratum in: Sex Transm Infect. 2007 Dec;83(7):594. Randell, P [added]; Mandalia S[added]; Asboe, D[added]; Boag, FC[added].

47.

Sexual dysfunction in HIV-positive men is multi-factorial: a study of prevalence and associated factors.

Asboe D, Catalan J, Mandalia S, Dedes N, Florence E, Schrooten W, Noestlinger C, Colebunders R.

AIDS Care. 2007 Sep;19(8):955-65.

PMID:
17851990
48.

A virological benefit from an induction/maintenance strategy: the Forte trial.

Asboe D, Williams IG, Goodall RL, Darbyshire JH, Hooker MH, Babiker AG; Forte Steering Committee.

Antivir Ther. 2007;12(1):47-54.

PMID:
17503747
49.
50.

Screening for syphilis in HIV-positive men who have sex with men (MSM).

Cohen CE, Winston A, Asboe D, Boag F, Hawkins DA.

Int J STD AIDS. 2006 Feb;17(2):142. No abstract available.

PMID:
16464283

Supplemental Content

Support Center